SELLAS Life Sciences Group, Inc.
SLSNasdaq
$13.19
↑ +12.3%Jul 17 close · end-of-day
Price
1Y↑ +587.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.3B
Enterprise Value
$2.2B
P/E
—
P/S
—
P/B
21.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$29.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-27.4%
ROIC
-7890.7%
Debt / Equity
—
Net Cash
$107.1M
Return 1Y
+594.2%
Company profile
SELLAS Life Sciences Group, Inc. focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapy that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials. The company was founded in 2012 and is headquartered in New York, New York.
- CEO
- Angelos M. Stergiou
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- New York
- Website
- sellaslifesciences.com
Management & directors
- Stergiou Andelos M.President and CEO
- Burns John ThomasCFO
- Cicic DraganSVP, Chief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
SLS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.05↓ -28.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $7.6M | $1.0M | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$17.0M | -$25.3M | -$42.0M | -$37.9M | -$31.5M | -$28.3M |
| Net income | -$16.8M | -$20.7M | -$41.3M | -$37.3M | -$30.9M | -$26.9M |
| Diluted EPS | -$2.11 | -$1.34 | -$2.13 | -$1.34 | -$0.50 | -$0.25 |
| Operating cash flow | -$10.4M | -$26.0M | -$23.8M | -$31.4M | -$35.4M | -$28.4M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -893.8% | -332.8% | -4195.0% | — | — | — |
| Net margin | -881.9% | -272.4% | -4130.1% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.6M | -$7.3M | -$6.9M | -$6.1M | -$6.9M | -$7.1M | -$8.3M | -$9.3M |
| Net income | -$7.5M | -$7.1M | -$6.7M | -$5.8M | -$6.6M | -$6.8M | -$7.7M | -$8.4M |
| Diluted EPS | -$0.13 | -$0.10 | -$0.06 | -$0.07 | -$0.07 | -$0.06 | -$0.05 | -$0.05 |
| Operating cash flow | -$9.7M | -$7.8M | -$7.2M | -$9.1M | -$7.3M | -$7.1M | -$4.9M | -$8.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 18, 2026
- 2d agoWill Near-Complete REGAL Phase 3 GPS Data and New Executive Terms Change SELLAS Life Sciences Group's (SLS) Narrativefinance.yahoo.com
- 2d agoSELLAS Life Sciences Group (SLS) Stock Looks Rich On Book Value Yet Strong On Returnsfinance.yahoo.com
- 2d agoSELLAS Life Sciences Group (SLS) Stock Pricey Following Phase 3 Trial Buzzfinance.yahoo.com
Jul 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Andelos M.· President and CEO | Award | 1,065,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Varian John | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | VAN NOSTRAND ROBERT L | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | SCHEINBERG DAVID A | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | CICIC DRAGAN· SVP, Chief Development Officer | Award | 300,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Burns John Thomas· CFO | Award | 300,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Wasman Jane | Award | 50,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Kalin Katherine Bach | Award | 50,000 | $0.00 | $0.00 | filing |
| 2025-12-03 | Stergiou Andelos M.· President and CEO | J | 187,066 | $1.50 | $280,599.00 | filing |
| 2025-12-03 | CICIC DRAGAN· SVP, Chief Development Officer | J | 63,800 | $1.50 | $95,700.00 | filing |
| 2025-12-03 | Burns John Thomas· CFO | J | 58,592 | $1.50 | $87,888.00 | filing |
| 2025-11-19 | Kalin Katherine Bach | Buy | 63,400 | $1.59 | $100,806.00 | filing |
Latest 12 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.